Vaxcyte (PCVX) News Today $85.30 -2.53 (-2.88%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Why Vaxcyte, Inc. (PCVX) Is One of the Best Russell 2000 Stocks to Invest in According to Analysts?January 18 at 7:57 PM | msn.comInsider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) Director Sells 6,250 Shares of StockJanuary 18 at 6:14 AM | insidertrades.comVaxcyte (NASDAQ:PCVX) Trading Up 7.8% - Should You Buy?Vaxcyte (NASDAQ:PCVX) Trading Up 7.8% - Time to Buy?January 17 at 5:45 PM | marketbeat.comTeri Loxam Sells 6,250 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) StockVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) Director Teri Loxam sold 6,250 shares of the firm's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the transaction, the director now directly owns 7,175 shares of the company's stock, valued at approximately $610,664.25. This represents a 46.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.January 17 at 4:55 PM | marketbeat.comBrokers Set Expectations for Vaxcyte FY2029 EarningsJanuary 16, 2025 | americanbankingnews.comVaxcyte (NASDAQ:PCVX) Stock Price Up 7.8% - Still a Buy?Vaxcyte (NASDAQ:PCVX) Trading 7.8% Higher - Time to Buy?January 15, 2025 | marketbeat.comVaxcyte’s VAX-A1 Vaccine: A Promising Contender in the Global Fight Against Group A StrepJanuary 15, 2025 | markets.businessinsider.comLeerink Partnrs Forecasts Vaxcyte FY2029 EarningsVaxcyte, Inc. (NASDAQ:PCVX - Free Report) - Investment analysts at Leerink Partnrs issued their FY2029 EPS estimates for shares of Vaxcyte in a note issued to investors on Sunday, January 12th. Leerink Partnrs analyst D. Risinger anticipates that the company will earn $2.42 per share for the yearJanuary 14, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Harbor Capital Advisors Inc.Harbor Capital Advisors Inc. grew its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 15.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 74,907 shares of the company's stock aJanuary 11, 2025 | marketbeat.com17,502 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Bought by Diversified Trust CoDiversified Trust Co purchased a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 17,502 shares of the company's stock, valued at approximatelJanuary 9, 2025 | marketbeat.comKuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law FirmJanuary 7, 2025 | prnewswire.comVaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Recommendation of "Buy" from BrokeragesVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) has been given an average rating of "Buy" by the eight research firms that are covering the stock, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages thatJanuary 6, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) COO Sells $669,280.00 in StockVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) COO Jim Wassil sold 8,000 shares of the business's stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $83.66, for a total value of $669,280.00. Following the transaction, the chief operating officer now owns 205,695 shares of the company's stock, valued at approximately $17,208,443.70. This trade represents a 3.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.January 3, 2025 | marketbeat.comPrincipal Financial Group Inc. Has $6.02 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)Principal Financial Group Inc. boosted its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 186.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,702 shares of the company's stocJanuary 2, 2025 | marketbeat.comVaxcyte (NASDAQ:PCVX) Shares Down 5.8% - Here's WhyVaxcyte (NASDAQ:PCVX) Shares Down 5.8% - Here's What HappenedDecember 27, 2024 | marketbeat.comIs Vaxcyte, Inc. (PCVX) the Best Performing Biotech Stock in 2024?December 23, 2024 | msn.comVaxcyte’s Promising Pipeline and Strategic Positioning: A Buy Recommendation Amidst Market ChallengesDecember 22, 2024 | markets.businessinsider.comGoldman Sachs Initiates Coverage of Vaxcyte (PCVX) with Buy RecommendationDecember 21, 2024 | msn.comVaxcyte a new buy at Goldman Sachs on vaccine platform, pneumonia assetDecember 20, 2024 | msn.comVaxcyte initiated with a Buy at Goldman SachsDecember 20, 2024 | markets.businessinsider.comThe Goldman Sachs Group Begins Coverage on Vaxcyte (NASDAQ:PCVX)The Goldman Sachs Group began coverage on shares of Vaxcyte in a report on Friday. They set a "buy" rating and a $135.00 target price on the stock.December 20, 2024 | marketbeat.comInsider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells 8,000 Shares of StockDecember 20, 2024 | insidertrades.comAndrew Guggenhime Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) StockVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total value of $710,240.00. Following the completion of the sale, the chief financial officer now owns 109,491 shares of the company's stock, valued at $9,720,610.98. The trade was a 6.81 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.December 19, 2024 | marketbeat.comKuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law FirmDecember 19, 2024 | globenewswire.comLord Abbett & CO. LLC Boosts Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)Lord Abbett & CO. LLC lifted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 26.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 312,425 shares of the company's stock after purchasing an additional 66,183 shares durDecember 15, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Franklin Resources Inc.Franklin Resources Inc. lifted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 13.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,786,335 shares of the company's stock after buying anDecember 15, 2024 | marketbeat.comGeode Capital Management LLC Has $308.68 Million Position in Vaxcyte, Inc. (NASDAQ:PCVX)Geode Capital Management LLC raised its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 10.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,700,782 shares of the company's stock after buying an additional 259December 15, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Receives Average Recommendation of "Buy" from AnalystsVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) has received a consensus rating of "Buy" from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12 month price target among brokeragesDecember 12, 2024 | marketbeat.comWhy Wall Street Rates These 2 Russell 2000 Stocks a “Strong Buy”December 12, 2024 | msn.comInsider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells 2,366 Shares of StockDecember 11, 2024 | insidertrades.comVaxcyte, Inc. (NASDAQ:PCVX) is Frazier Life Sciences Management L.P.'s 7th Largest PositionFrazier Life Sciences Management L.P. lowered its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 15.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 879,405 shares of the company's stock after selling 160,00December 10, 2024 | marketbeat.comY Intercept Hong Kong Ltd Has $2.97 Million Stake in Vaxcyte, Inc. (NASDAQ:PCVX)Y Intercept Hong Kong Ltd lifted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 148.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,019 shares of the companyDecember 10, 2024 | marketbeat.comZacks Investment Management Invests $1.56 Million in Vaxcyte, Inc. (NASDAQ:PCVX)Zacks Investment Management bought a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 13,645 shares of the company's stock, valued atDecember 10, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by State Street CorpState Street Corp raised its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 1.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,405,743 shares of the company's stock after acquiring an additional 38,596 shares during the quarterDecember 10, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) SVP Sells $457,450.00 in StockDecember 10, 2024 | insidertrades.comWhat Makes Vaxcyte (PCVX) An Investment Bet?December 9, 2024 | msn.comPier Capital LLC Sells 67,402 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)Pier Capital LLC lowered its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 58.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,567 shares of the company's stock after seDecember 8, 2024 | marketbeat.comVaxcyte: Promising Developments and Strategic Advancements Boost Confidence in Stock PotentialDecember 6, 2024 | markets.businessinsider.comVaxcyte, Inc. (NASDAQ:PCVX) is RA Capital Management L.P.'s 2nd Largest PositionRA Capital Management L.P. grew its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 5.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,689,190 shares of the company's stock after purchasinDecember 5, 2024 | marketbeat.comPoint72 Asset Management L.P. Takes Position in Vaxcyte, Inc. (NASDAQ:PCVX)Point72 Asset Management L.P. acquired a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 359,796 shares of the company'sDecember 5, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Polar Asset Management Partners Inc.Polar Asset Management Partners Inc. lessened its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 45.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 54,000 shares of the company's stock after selDecember 5, 2024 | marketbeat.com27,433 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Purchased by Bank of Montreal CanBank of Montreal Can purchased a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 27,433 shares of the company's stock, valued at approximately $3,104,000. Other large investors have alDecember 5, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Position Trimmed by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC lowered its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 13.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 130,249 shares of the company's stock after selling 19,942 shares duDecember 4, 2024 | marketbeat.comMaven Securities LTD Acquires New Position in Vaxcyte, Inc. (NASDAQ:PCVX)Maven Securities LTD purchased a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 129,700 shares of the company's stock, valued at approximately $14,821,0December 4, 2024 | marketbeat.comVaxcyte initiates Phase 2 study of VAX-31December 4, 2024 | markets.businessinsider.comJim Wassil Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) StockDecember 4, 2024 | insidertrades.com31,000 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Acquired by Bamco Inc. NYBamco Inc. NY bought a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 31,000 shares of the company's stock, valued at approximately $3,542,000. Several other institutioDecember 4, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stake in Vaxcyte, Inc. (NASDAQ:PCVX)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 38.0% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 408,274 shares of the company's stock aDecember 4, 2024 | marketbeat.comVaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in InfantsDecember 3, 2024 | globenewswire.comVaxcyte, Inc. (NASDAQ:PCVX) is HighVista Strategies LLC's 3rd Largest PositionHighVista Strategies LLC grew its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 38.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 44,661 shares of the company's stock after buying an additionalDecember 3, 2024 | marketbeat.com Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address PCVX Media Mentions By Week PCVX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PCVX News Sentiment▼0.700.44▲Average Medical News Sentiment PCVX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PCVX Articles This Week▼126▲PCVX Articles Average Week Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Takeda Pharmaceutical News Today argenx News Today BioNTech News Today Teva Pharmaceutical Industries News Today BeiGene News Today Summit Therapeutics News Today Genmab A/S News Today Viatris News Today Intra-Cellular Therapies News Today Moderna News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PCVX) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
